raavrh74.mhck7.dysf.dv
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02710500)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DysferlinSupplementation
DYSF supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raavrh74.mhck7.dysf.dv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05906251 | Phase 1 | May 22, 2023 | Sarepta Therapeutics |
| NCT02710500 | Phase 1 | Mar 1, 2016 | Ohio State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Sarepta Therapeutics | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1